239 related articles for article (PubMed ID: 22836659)
1. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
[TBL] [Abstract][Full Text] [Related]
2. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
3. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
4. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
[TBL] [Abstract][Full Text] [Related]
5. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
6. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.
Perosky JE; Khoury BM; Jenks TN; Ward FS; Cortright K; Meyer B; Barton DK; Sinder BP; Marini JC; Caird MS; Kozloff KM
Bone; 2016 Dec; 93():79-85. PubMed ID: 27641475
[TBL] [Abstract][Full Text] [Related]
7. Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.
Sinder BP; Lloyd WR; Salemi JD; Marini JC; Caird MS; Morris MD; Kozloff KM
Bone; 2016 Mar; 84():222-229. PubMed ID: 26769006
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
[TBL] [Abstract][Full Text] [Related]
11. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
Uveges TE; Kozloff KM; Ty JM; Ledgard F; Raggio CL; Gronowicz G; Goldstein SA; Marini JC
J Bone Miner Res; 2009 May; 24(5):849-59. PubMed ID: 19113917
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
13. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
14. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.
Meganck JA; Begun DL; McElderry JD; Swick A; Kozloff KM; Goldstein SA; Morris MD; Marini JC; Caird MS
Bone; 2013 Sep; 56(1):204-12. PubMed ID: 23774443
[TBL] [Abstract][Full Text] [Related]
15. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania.
Scheiber AL; Barton DK; Khoury BM; Marini JC; Swiderski DL; Caird MS; Kozloff KM
J Bone Miner Res; 2019 Dec; 34(12):2301-2310. PubMed ID: 31441963
[TBL] [Abstract][Full Text] [Related]
17. The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment.
Liu Y; Ju M; Wang Z; Li J; Shao C; Fu T; Jing Y; Zhao Y; Lv Z; Li G
Biomed Pharmacother; 2020 Aug; 128():110235. PubMed ID: 32454289
[TBL] [Abstract][Full Text] [Related]
18. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
[TBL] [Abstract][Full Text] [Related]
19. A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.
Surowiec RK; Battle LF; Ward FS; Schlecht SH; Khoury BM; Robbins C; Wojtys EM; Caird MS; Kozloff KM
Bone; 2020 Jan; 130():115118. PubMed ID: 31678490
[TBL] [Abstract][Full Text] [Related]
20. Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.
Davis MS; Kovacic BL; Marini JC; Shih AJ; Kozloff KM
Bone; 2012 Mar; 50(3):784-91. PubMed ID: 22207275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
